Tobacco Abstinence Syndrome Clinical Trial
This FDA-approved (IND# 120700) study will evaluate efficacy of intranasal insulin in reducing snack intake and reducing postprandial free fatty acid levels in abstinent smokers.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01781234 -
Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome
|
Phase 2 |